Abstract
The incidence of heart failure (HF) increases with advancing age with a lifetime risk for the diagnosis of 20 %. There are physiological changes that predispose the elderly to developing HF and small insults may rapidly precipitate decompensation of symptoms. There are special challenges in diagnosing and managing elderly patients with HF, challenges that biomarkers can help mitigate. Natriuretic peptides such as B-type natriuretic peptide and N-terminal proBNP are established biomarkers that have been proven to accurately diagnose and prognosticate HF. There are additional promising novel biomarkers that may be of use.
Relationship with industry: Dr. Januzzi reports the following disclosures: (1) Roche Diagnostics: research grants, consultancy; (2) Siemens Diagnostics: research grants; (3) Critical Diagnostics: research grants, consultancy; (4) BRAHMS: research grants. (5) Singulex: research grants Dr. Gaggin does not have disclosures.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- ACC:
-
American College of Cardiology
- ACE:
-
Angiotensin converting enzyme
- ADHERE:
-
Acute Decompensated Heart Failure National Registry
- AHA:
-
American Heart Association
- ANP:
-
Atrial natriuretic peptide
- ARB:
-
Angiotensin II receptor blockers
- BACH:
-
Biomarkers in Acute Heart Failure
- BATTLESCARRED:
-
The NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death
- BNP:
-
B-type natriuretic peptide
- CHS:
-
Cardiovascular Health Study
- GDF:
-
Growth differentiation factor
- HF:
-
Heart failure
- HFpEF:
-
Heart failure with preserved ejection fraction
- hsTnT:
-
Highly sensitive troponin T
- LVSD:
-
Left ventricular systolic dysfunction
- MR-proADM:
-
Mid-regional pro adrenomedullin
- MR-proANP:
-
Mid-regional pro atrial natriuretic peptide
- NP:
-
Natriuretic peptide(s)
- NT-proBNP:
-
Amino-terminal B-type natriuretic peptide
- PCWP:
-
Pulmonary capillary wedge pressure
- PRIDE:
-
ProBNP Investigation of Dyspnea in the Emergency Department
- PROTECT:
-
ProBNP Outpatient Tailored Chronic Heart Failure Therapy
- REDHOT:
-
Rapid Emergency Department Heart Failure Outpatient Trial
- sST2:
-
Soluble ST2
- TIME-CHF:
-
Trial of Intensified versus Standard Medical therapy in Elderly Patients with Congestive HF
- Val-HeFT:
-
Valsartan Heart Failure
References
Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25(18):1614–9. Epub 2004/09/08.
Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72. Epub 2002/12/11.
Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26(6):447–62. Epub 2008/05/21.
Hajdu MA, Heistad DD, Siems JE, Baumbach GL. Effects of aging on mechanics and composition of cerebral arterioles in rats. Circ Res. 1990;66(6):1747–54. Epub 1990/06/01.
Robert L. Aging of the vascular-wall and atherosclerosis. Exp Gerontol. 1999;34(4):491–501. Epub 2000/05/19.
Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001;38(2):274–9. Epub 2001/08/18.
Linzbach AJ, Akuamoa-Boateng E. [Changes in the aging human heart. I. Heart weight in the aged] Die Alternsveranderungen des menschlichen Herzens. I. Das Herzgewicht im Alter. Klin Wochenschr. 1973;51(4):156–63. Epub 1973/02/15.
Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991;68(6):1560–8. Epub 1991/06/01.
Janczewski AM, Lakatta EG. Modulation of sarcoplasmic reticulum Ca(2+) cycling in systolic and diastolic heart failure associated with aging. Heart Fail Rev. 2010;15(5):431–45. Epub 2010/04/27.
Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73(2):413–67. Epub 1993/04/01.
Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol. 2008;52(7):534–40. Epub 2008/08/09.
Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988;77(3):607–12. Epub 1988/03/01.
Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clin Geriatr Med. 2000;16(3):445–56. Epub 2000/08/05.
Chronic Conditions: Making the case for ongoing care. September 2004 update. Johns Hopkins and the Robert Wood Johnson Foundation’s Partnership for Solutions [cited 2012 October 1]. Available from: http://www.partnershipforsolutions.org/DMS/files/chronicbook2004.pdf. Last Accessed on 25 Oct 2012
Kitzman DW. Heart failure with normal systolic function. Clin Geriatr Med. 2000;16(3):489–512. Epub 2000/08/05.
McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350(9081):829–33. Epub 1997/10/06.
Weinhouse GL. Pulmonary artery catheterization: Indications and complications. 2012 [updated May 15, 2012; cited 2012 October 3]; UpToDate. Available from: http://www.uptodate.com/contents/pulmonary-artery-catheterization-indications-and-complications?source=search_result&search=right+heart+cath&selectedTitle=2%7E150#H8. Last Accessed on 25 Oct 2012.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46. Epub 2007/08/19.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90. Epub 2009/04/11.
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25. Epub 2005/01/12.
Rochon P. Drug prescribing for older adults. UpToDate, Inc.; 2012. http://www.uptodate.com/contents/drug-prescribing-for-older-adults. Last Accessed on 25 Oct 2012.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479. Epub 2009/03/28.
Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–68. Epub 2007/12/25.
Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87(4):1402–12.
Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM. Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail. 2009;11(9):832–9.
van Kimmenade RR, Januzzi Jr JL, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009;53(10):884–90. Epub 2009/03/07.
Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993;16(7):553–7. Epub 1993/07/01.
Januzzi Jr JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948–54. Epub 2005/04/12.
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–7. Epub 2002/07/19.
Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141(3):367–74. Epub 2001/03/07.
Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47(3):582–6. Epub 2006/02/07.
Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47(1):91–7. Epub 2006/01/03.
McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571–9. Epub 2003/03/04.
Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330–7. Epub 2005/11/19.
Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90(3):254–8. Epub 2002/07/20.
Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47(2):345–53. Epub 2006/01/18.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976–82. Epub 2002/09/13.
Kim HN, Januzzi Jr JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015–9. Epub 2011/05/11.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–63. Epub 2004/02/13.
McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006;47(5):874–80. Epub 2006/04/06.
deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55(5):441–50. Epub 2010/02/02.
Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943–50. Epub 2007/05/15.
Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44(6):1328–33.
Januzzi Jr JL, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315–20. Epub 2006/02/16.
Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52(8):1528–38. Epub 2006/06/17.
Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997–1003. Epub 2008/09/13.
Kim HN, Januzzi Jr JL. Biomarkers in the management of heart failure. Curr Treat Opt Cardiovasc Med. 2010;12(6):519–31. Epub 2010/11/11.
Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422–30. Epub 2009/08/25.
Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010;170(6):507–14. Epub 2010/03/24.
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92. Epub 2009/01/30.
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53–60. Epub 2010/02/02.
Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail. 2012;18(8):626–34. Epub 2012/08/04.
Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062–76. Epub 2010/05/08.
Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL, Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012. Epub 2012/05/31.
Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010;12(4):338–47. Epub 2010/01/26.
Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group J Am Coll Cardiol. 2001;37(7):1781–7. Epub 2001/06/13.
Januzzi JL, Jr., Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012. Epub 2012/06/30.
Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011;13(1):37–42. Epub 2010/12/15.
Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125(2):280–8. Epub 2011/12/06.
deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494–502. Epub 2010/11/17.
Dieplinger B, Januzzi Jr JL, Steinmair M, Gabriel C, Poelz W, Haltmayer M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma–the Presage ST2 assay. Clin Chim Acta. 2009;409(1–2):33–40. Epub 2009/08/25.
Rehman SU, Mueller T, Januzzi Jr JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52(18):1458–65. Epub 2008/11/20.
Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4(2):180–7. Epub 2010/12/24.
Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387–95. Epub 2010/09/22.
de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–8. Epub 2010/12/30.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Funding: Dr. Gaggin is supported in part by the Clark Fund for Cardiac Research Innovation. Dr. Januzzi is supported in part by the Roman W. DeSanctis Clinical Scholar Endowment.
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gaggin, H.K., Januzzi, J.L. (2014). Biomarkers and Optimal Management of Heart Failure in the Aging Population. In: Jugdutt, B. (eds) Aging and Heart Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0268-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0268-2_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0267-5
Online ISBN: 978-1-4939-0268-2
eBook Packages: MedicineMedicine (R0)